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Abstract: Low dose aspirin therapy plays a fundamental role in both the primary and secondary 
prevention of cardiovascular events. Although the evidence using low dose aspirin for secondary 
prevention is well-established, the decision to use aspirin for primary prevention is based on 
an evaluation of the patient’s risk of cardiovascular events compared to their risk of adverse 
events, such as bleeding. In addition to the risk of bleeding associated with long term aspirin 
administration, upper gastrointestinal side effects, such as dyspepsia often lead to discontinuation 
of therapy, which places patients at an increased risk for cardiovascular events. One option to 
mitigate adverse events and increase adherence is the addition of esomeprazole to the medication 
regimen. This review article provides an evaluation of the literature on the concomitant use of 
aspirin and esomeprazole available through February 2013. The efficacy, safety, tolerability, 
cost effectiveness, and patient quality of life of this regimen is discussed. A summary of the 
pharmacokinetic and pharmacodynamic interactions between aspirin and esomeprazole, as 
well as other commonly used cardiovascular medications are also reviewed. The addition of 
esomeprazole to low dose aspirin therapy in patients at high risk of developing gastric ulcers for 
the prevention of cardiovascular disease, significantly reduced their risk of ulcer development. 
Pharmacokinetic and pharmacodynamic studies suggested that esomeprazole did not affect the 
pharmacokinetic parameters or the antiplatelet effects of aspirin. Therefore, for those patients 
who are at a high risk of developing a gastrointestinal ulcer, the benefit of adding esomeprazole 
likely outweighs the risks of longer term proton pump inhibitor use, and the combination can 
be recommended. Administering the two agents separately may also be more economical. 
On the other hand, for those patients at lower risk of developing a gastrointestinal ulcer, both 
the additional risk and cost make the inclusion of a proton pump inhibitor unwarranted.
Keywords: aspirin, esomeprazole, proton pump inhibitors, cardiovascular event prevention
Introduction
Cardiovascular disease is the number one cause of mortality and morbidity in 
the United States (US). An estimated 82.6 million Americans have one or more types of 
cardiovascular disease.1 Among them, 16.3 million have coronary heart disease (CHD).1 
Low dose aspirin (75–325 mg per day) use is associated with a significant reduction 
in the risk for cardiovascular events.2,3 The role of low dose aspirin for secondary 
  prevention (in individuals with coronary artery disease, peripheral vascular disease, 
or cerebrovascular disease) of cardiovascular events is well established, while its use 
in primary prevention is more controversial.4,5 The decision for aspirin use as primary 
prevention therapy is dependent on a balance of an individual’s risk of cardiovascular 
events and adverse treatment effects, such as bleeding.6 Odd ratios for bleeding, in 
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case-control studies of low dose aspirin use, range between 
1.3–3.2.7 The US Food and Drug Administration (FDA) 
has not been adequately persuaded that there is sufficient 
  evidence of a net benefit for aspirin use in primary preven-
tion.8 The American Heart Association (AHA), however, 
recommends low dose aspirin in individuals with an estimated 
$ 10% risk of a cardiovascular event over a 10-year period.9 
Similarly, the US Preventive Services Taskforce (USPSTF) 
recommends aspirin in men aged 45–79 years in whom the 
benefit of a reduction in myocardial infarction (MI) outweighs 
the harm of an increased risk of gastrointestinal bleeding, 
and in women aged 55–79 years in whom the benefit of a 
reduction in the risk of ischemic stroke outweighs the same 
risk of harm.10 For older adults, they recommend a 12% risk 
of a cardiovascular event over 10 years as the cut-off when 
the benefit exceeds the risk in those aged 70–79 years. For 
people with diabetes, the American Diabetes Association 
(ADA) acknowledges the lack of a clear role for aspirin in 
primary prevention, and currently recommends its use in 
patients with diabetes who have a 10-year cardiovascular 
disease risk of over 10%.11,12
Although tolerable to most patients, the impact of adverse 
effects associated with a long-term aspirin regimen is not 
negligible, especially given the large number of subjects 
under aspirin treatment worldwide and the long term duration 
of therapy. Keeping patients with high cardiovascular 
risk on low dose aspirin therapy is an important part of 
cardiovascular risk management. Indeed, poor compliance 
has been associated with adverse cardiovascular outcomes.13,14 
Discontinuation of low dose aspirin has been reported to 
significantly increase death, MI, stroke, and major adverse 
CV events, in a meta-analysis of six prospective studies 
comprising more than 50,000 patients at risk for coronary 
artery disease.15 The extent and reasons for noncompliance 
and inappropriate discontinuation of low dose aspirin therapy 
are not completely understood. However, adverse gastroin-
testinal symptoms, coronary artery disease, older age, female 
gender, and lower educational level have been associated 
with a lower level of adherence.16,17
While some factors that can cause nonadherence to 
aspirin therapy may not be amendable, improvement of 
gastrointestinal intolerance and bleeding may be one of the 
ways to improve compliance. There are multiple strategies 
that have been used to mitigate the adverse gastrointestinal 
effects of low dose aspirin, such as adding a gastroprotective 
agent that may include either a mucosal protectant, such 
as misoprostol or an acid suppressive agent such as an 
H2-  receptor antagonist or a proton pump inhibitor and 
eradicating Helicobacter pylori.18 Switching to an alternative 
antiplatelet agent, such as clopidogrel, has also been recom-
mended to prevent cardiovascular events.19 However, this 
strategy is not applicable to the many patients who require 
dual antiplatelet therapy due to an acute coronary syndrome 
event or who have had coronary stents placed. Proton pump 
inhibitors reduce the risk of aspirin-induced ulcer bleeding 
by up to 10-fold.20,21 They have also been demonstrated 
to be superior to H2-receptor antagonists in preventing 
upper gastrointestinal bleeding in patients with acute coro-
nary syndrome.22 Combination therapy with proton pump 
i  nhibitors has been advocated for patients at high risk for 
ulcer bleeding who are taking aspirin and other nonsteroid 
anti-inflammatory agents (NSAIDS).23,24 Patients considered 
to be at high risk for ulcer bleeding are those who have had a 
previous ulcer event, age . 65 years, patients receiving con-
comitant anticoagulation or corticosteroid therapy, patients 
on low dose aspirin therapy for vascular prophylaxis, and 
those with severe rheumatoid arthritis requiring high doses 
of NSAIDs. Despite these recommendations, cotherapy with 
proton pump inhibitors or H2-antagonists for the prevention 
of low dose aspirin-related gastrointestinal adverse events 
in patients with a history of peptic ulcer disease is often 
under prescribed. Based on a drug utilization study of 30,015 
aspirin prescriptions, coprescribing of aspirin and proton 
pump inhibitors or H2-antagonists occurred only 3.46% 
of the time.25 A single, fixed dose capsule combining low 
dose aspirin with the proton pump inhibitor esomeprazole 
(Axanum® formulated as enteric coated pellets) has been 
developed and approved in the European Union to reduce 
the risk of gastric and/or duodenal (peptic) ulcers and to 
potentially improve patient adherence. The fixed dose 
capsule contains aspirin 81 mg and esomeprazole 20 mg.26 
This article reviews the pharmacological properties, clinical 
efficacy and tolerability of low dose aspirin/esomeprazole in 
patients requiring low dose aspirin therapy who are at risk 
of aspirin associated peptic ulcers.
Methodology
Peer-reviewed clinical trials, review articles, and relevant treat-
ment guidelines, published in English and relating to human 
(not animal), were identified from MEDLINE and Current Con-
tent database (both January 1, 1966 to February 1, 2013) using 
search terms aspirin, esomeprazole,   proton pump inhibitors, 
pharmacology, pharmacokinetics, pharmacodynamics, phar-
macoeconomics, and cost-  effectiveness and were evaluated. 
This revealed 14 total articles, including four review articles 
and seven clinical trials (  including pharmacokinetics and 
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pharmacodynamics study). Review articles are not discussed 
in this review as we are focusing on clinical implications.
Pharmacokinetics and pharmacodynamics
Pharmacokinetic and pharmacodynamic studies are important 
to identify drug-drug interactions with the coadministration 
of low dose aspirin and proton pump inhibitors to ensure that 
while providing gastric protection, the addition of a proton 
pump inhibitor does not decrease the cardiovascular protective 
effects of aspirin. A pharmacokinetic evaluation was conducted 
with 55 male and female healthy volunteers (mean age 27.1 
years, mean body mass index [BMI] 23 kg/m2) who were 
randomized in an open 3-way crossover study to receive either 
uncoated aspirin 325 mg alone, esomeprazole 40 mg alone, or 
the combination of the two drugs (in separate tablet/capsules) 
for 5 days separated by at least a 13 day washout period.27 There 
were no significant   pharmacokinetic interactions observed 
after repeated coadministration. The 90% confidence intervals 
for the geometric means of the steady-state area under the 
plasma concentration-time curve during the dosing interval 
(AUCΐ) and the observed maximum plasma concentration 
(Cmax) ratios were within the predefined bioequivalence interval 
of 80% to 125% when comparing aspirin alone with aspirin 
plus esomeprazole as well as when comparing esomeprazole 
alone with esomeprazole plus aspirin. The time to Cmax (tmax) 
and the terminal half-life (t1/2) were also similar for each agent 
individually and in combination.
The bioequivalence of uncoated aspirin 325 mg and 
esomeprazole 40 mg administered as individual components 
compared to a single-capsule formulation was also evaluated in 
an open-label, randomized, 2-way crossover study of 49 male 
and female healthy volunteers (mean age 28 years, mean 
BMI 24.1 kg/m2).28 Each participant received a single dose 
of the treatment regimen followed by at least a 6-day washout 
period. The two therapies were considered to be bioequivalent 
if the 94% confidence interval of the geometric mean ratios of 
AUC and Cmax were within the predefined interval of 80% to 
125%. The study results confirmed bioequivalence and also 
demonstrated similar kinetics for tmax and t1/2.
Both of these studies used higher doses than those 
manufactured in the fixed dose combination capsule in an 
attempt to maximize the possibility of finding an interaction 
between the two drugs. Additionally, generalizability may be 
limited to the general population since both of these studies 
utilized the uncoated aspirin tablets which may not be a true 
reflection of clinical practice, as those patients at high risk 
of a gastrointestinal complication are likely to be taking 
either buffered aspirin or enteric coated aspirin. Of note, 
similar pharmacokinetic studies have been performed using 
omeprazole as the proton pump inhibitor of choice, and results 
from those studies showed no clinically significant difference 
in bioavailability when omeprazole was administered with 
uncoated aspirin and enteric-coated aspirin.29
Although the above studies suggest that there is no 
  pharmacokinetic interaction between the two agents when 
coadministered either in a fixed dose capsule or   concomitantly 
as individual drugs, there is some   retrospective data to   suggest 
that a pharmacodynamic interaction may exist between aspi-
rin and proton pump inhibitors in terms of a reduction in the 
antiplatelet action of aspirin. This has not been confirmed by 
prospective studies.30–32 A recent study by Andersson et al ran-
domized 29 male and female healthy volunteers (mean age 50 
years, mean BMI 26 kg/m2) in an open-label 2-way crossover 
study to either aspirin 81 mg for 5 days or esomeprazole 20 mg 
in combination with aspirin 81 mg for 5 days with at least a 
14-day washout period.33 A pharmacodynamic interaction was 
evaluated by assessing the relative change in aspirin reactivity 
units using the VerifyNow (Accumetrics, San Diego, CA, USA) 
aspirin assay after 5 days of treatment versus baseline. No phar-
macodynamic interactions were observed based the geometric 
mean ratio of day six to baseline aspirin reactivity unit values. 
There was also no difference in the secondary endpoint of 
suppression of serum thromboxane B2.
Efficacy
There have been no published clinical trials evaluating the 
efficacy of a fixed combination of esomeprazole and aspi-
rin for the prevention of cardiovascular events. There have 
been, however, two randomized, double-blind, multinational, 
placebo-controlled clinical trials that evaluated the occurrence 
of peptic ulcers when esomeprazole was administered to 
patients at risk of developing ulcers while taking low dose 
aspirin (75–325 mg) for 26 weeks.34,35 The primary efficacy 
endpoint for both studies was the occurrence of an endoscopy 
confirmed gastric and/or duodenal ulcer and mucosal break 
of at least 3 mm.
The Efficacy of esomprazole (20 mg once daily) for 
reducing the risk of gastrointestinal ulcers associated with 
continuous use of low-dose aspirin (ASTERIX) study 
included patients who were at moderate to high risk of 
developing a peptic ulcer (defined as being $60 years old 
and having a negative H. pylori test with no evidence of a 
peptic ulcer at baseline) and required continuous low dose 
aspirin for secondary prevention of   cardiovascular events.34 
Patients were then randomized in a 1:1 ratio to either esome-
prazole 20 mg or placebo in addition to their baseline aspirin 
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regimen. Secondary efficacy outcomes included esophageal 
ulcers and upper gastrointestinal symptoms assessed by the 
investigators.
Results from the intention-to-treat population (n = 991) 
showed a 71% relative risk reduction in ulcer development 
when taking esomeprazole 20 mg compared to placebo. 
During the 26-week study period, 27 patients (5.4%) in the 
placebo group developed either a gastric or duodenal ulcer 
and 8 patients (1.6%) in the esomeprazole group devel-
oped a peptic ulcer (P = 0.0007 for life-table estimated at 
6 months); this difference was evident as early as 8 weeks 
into the study (P = 0.0061). The median ulcer size in both 
groups was 7 mm. Only one patient in each group had an 
ulcer greater than 10 mm and there were no gastric or duo-
denal ulcers less than 5 mm detected in the esomeprazole 
group (compared to 6 ulcers less than 5 mm in the placebo 
group). The difference in outcomes was most evident for 
those patients who developed an ulcer that was 5–10 mm in 
size, which occurred in 20 patients in the placebo group, and 
7 patients in the esomeprazole group. Erosive esophagitis 
was also lower in the esomeprazole group versus the placebo 
group (P , 0.001). The development of epigastric burning 
and heartburn was significantly decreased with the addition 
of esomeprazole (P , 0.05), but it had no effect on other 
upper gastrointestinal symptoms such as epigastric pain and 
discomfort, acid regurgitation, nausea, or vomiting.
The OBERON study (Prevention of peptic ulcers with 
esomeprazole in patients at risk of ulcer development treated 
with low-dose acetylsalicylic acid: a randomized, controlled 
trial) evaluated patients whose doctor prescribed or recom-
mended daily low dose aspirin and included patients on 
aspirin for both primary and secondary prevention, who were 
H. pylori negative and who were at high risk of developing 
a peptic ulcer (defined as age $ 18 years old with a docu-
mented history of an uncomplicated peptic ulcer, age $ 60 
years with one or more risk factors for a peptic ulcer, or aged 
$ 65 years).35 Patients were then randomized in a 1:1:1 ratio 
to esomeprazole 20 mg, esomeprazole 40 mg, or placebo in 
addition to their baseline aspirin regimen.
This study resulted in an 85% relative risk reduction in 
ulcer development for patients taking esomeprazole 40 mg 
(1.5%) compared to those taking placebo (7.4%) and an 
80% reduction in those taking esomeprazole 20 mg (1.1%) 
compared with those taking placebo in the intention-to-
treat population (n = 2426). The absolute risk reduction 
was 6.3% in the esomeprazole 40 mg group and 5.9% in 
the esomeprazole 20 mg group. This study did not evaluate 
gastrointestinal symptoms and did not report on ulcer size.
Both studies found that gastric ulcers were more prevalent 
than duodenal ulcers in all treatment groups. Additionally, post-
hoc analyses in both studies showed that esomeprazole signifi-
cantly decreased ulcer occurrence regardless of the dose of aspirin 
used (75–100 mg versus 101–325 mg). In both trials, compliance 
was assessed for the study drugs only (esomeprazole and placebo, 
not aspirin) and patients were considered to be compliant if they 
took their doses at least 75% of the time (ASTERIX compliance 
rates were around 85% and for OBERON compliance rates were 
around 94%). Compliance with aspirin was not evaluated in 
either of these studies. It is not known if coadministration with 
esomeprazole will enhance aspirin adherence.
Overall, the results from these studies demonstrated 
that for patients requiring continuous low dose aspirin for 
primary or secondary prevention of cardiovascular events 
who are at moderate to high risk of developing a peptic ulcer, 
administration of esomeprazole reduces the development of 
peptic ulcers. Additionally the OBERON trial showed that 
treatment with either esomeprazole 20 mg or 40 mg is equally 
efficacious. It is important to note that these patients were 
only followed up for 26 weeks whereas the typical patient on 
low dose aspirin therapy would require lifetime treatment. 
Additionally, ulcers were identified using endoscopy, which 
also may not be reflective of clinical practice.
Safety and tolerability
The ASTERIX and OBERON studies found that taking 
esomeprazole along with their current low dose aspirin regi-
men was well tolerated by patients. In the ASTERIX study, 
there were six bleeding events: four in the placebo group and 
two in the esomeprazole group. Both of the patients in the 
esomeprazole group had a bleed related to a preexisting ulcer 
history, whereas none of the patients in the placebo group 
had a history of ulcers. In the OBERON study, there were 
five bleeding events: two in the esomeprazole 20 mg group, 
three in the placebo group, and none in the esomeprazole 
40 mg group; no additional information was provided on the 
patients’ prior risk for developing a bleeding event.
In each of the three treatment groups of the OBERON 
study, 37% of patients experienced an adverse event. Fatal 
serious adverse events accounted for #0.5% of the total events 
and nonfatal serious adverse events accounted for another 5%. 
Although there were nine deaths in the study, with eight deaths 
in the esomeprazole treatment group, none of the deaths were 
found to be related to study drug administration. A cardiac-
related cause was responsible for five of the nine deaths 
  (myocardial infarction, n = 2 [one   esomeprazole 40 mg and one 
placebo recipient]),   cerebrovascular   accident (n = 1, esome-
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prazole 20 mg), cardiac arrest (n = 1, esomeprazole 20 mg), 
acute coronary syndrome (n = 1, esomeprazole 20 mg), sudden 
death (n = 1,   esomeprazole 40 mg). Adverse events leading 
to withdrawal of treatment occurred in 3.7% of the patients 
in the esomeprazole 40 mg group, 4.6% of the patients in the 
esomeprazole 20 mg group, and 5.2% of those in the placebo 
group.   Treatment related adverse events occurred in 4.2% of 
the patients in the esomeprazole 40 mg group, 4.9% of the 
patients in the esomeprazole 20 mg group, and 3.9% of those in 
the placebo group. The most   common adverse events included 
gastrointestinal symptoms (diarrhea, nausea, upper abdominal 
pain, constipation,   dyspepsia), headache, dizziness, respiratory 
complications (bronchitis,   influenza, nasopharyngitis, upper 
respiratory infections), back pain, urinary tract infections, and 
  hypertension. All of these events occurred in less than 4% of 
the population. Overall, about 2.5% of the adverse events were 
categorized as cardiac disorders with no clinically significant 
differences between the treatment groups.
The ASTERIX study investigators found that 7% of 
patients (n = 69) had a serious adverse event. Unlike the 
OBERON study, the most common serious adverse events 
were cardiac disorders, which accounted for approximately 
32% of all serious adverse events reported (8 and 14 patients, 
respectively, in the esomeprazole and placebo groups). 
Three patients in the placebo group experienced myocardial 
  infarction and there were no such events in the esomeprazole 
group. Adverse events led to withdrawal of treatment in 
45 patients, 3.9% of the patients in the esomeprazole group 
and 5.2% of those in the placebo group. No other complica-
tions were reported by the study investigators.
Results from these two trials suggest that esomeprazole 
in combination with low dose aspirin was well tolerated and 
raised no significant safety concerns. The safety profile of 
long-term proton pump inhibitor use must also be considered in 
the risk versus benefit analysis for prophylaxis of peptic ulcers 
associated with low dose aspirin use.   Epidemiological data 
have suggested that there may be an increased risk of vertebral 
and hip fractures with chronic proton pump   inhibitor use.36–40 
The reduction in gastric acid by proton pump inhibitors may 
also serve as an important risk factor for infection with acid-
labile bacteria, such as Clostridium difficile and pneumonia, 
and prevent absorption of key nutrients (Table 1).41–45
Potential interaction between 
esomeprazole and other  
cardiovascular medications
Although esomeprazole reduced incidence of peptic ulcer in 
patients who received chronic aspirin therapy for primary or 
secondary prevention in cardiovascular diseases, in order to 
decide if esomeprazole should be routinely added to aspi-
rin therapy, it is also important to consider other potential 
drug interactions that esomeprazole may have with other 
medications that are commonly prescribed to patients with 
cardiovascular diseases.
Similar  to  many  other  proton  pump  inhibitors, 
esomeprazole is metabolized by cytochrome P450 2C19, 
and it also has the ability to inhibit the same enzyme.46 
Clopidogrel and aspirin are commonly used together in 
patients with coronary artery diseases. Clopidogrel is an 
antiplatelet agent that requires cytochrome P450 2C19 
enzyme to convert to its pharmacologically active form. 
There has been considerable controversy regarding the 
risk of cardiovascular events from the potential interaction 
between clopidogrel and proton pump inhibitors, includ-
ing esomeprazole.47–49 In 2009, the FDA released warnings 
specifically against the concomitant use of omeprazole or 
esomeprazole with clopidogrel based on pharmacokinetic and 
platelet function data.50 However, the FDA also stated that 
they did not have sufficient information on the impact of other 
proton pump inhibitors. Nevertheless, it has been suggested 
that pantoprazole may be a safer option than omeprazole, 
based on clinical trial data demonstrating that omeprazole 
significantly affected the antiplatelet effect of clopidogrel, 
whereas pantoprazole did not. Given the multitude of platelet 
function tests, extent of individual variability and complex-
ity of the platelet regulation pathways, the consistency of 
the entire dataset should be considered before deciding on 
one proton pump inhibitor over another. A recent systematic 
review was performed including 18 platelet function studies 
as well as 33 clinical studies in patients with acute coronary 
syndrome or undergoing percutaneous coronary interven-
tion.51 In 70% of the laboratory studies, antiplatelet activity 
of clopidogrel was reduced by concomitant use of proton 
Table  1  Potential  long-term  adverse  effect  of  proton  pump 
inhibitors36–45
Decreased bone mineral density 
  increased risk of fractures: hip, vertebral, and wrist 
increased risk of infections 
  Enteric infections (eg, Clostridium difficile) 
    Respiratory infections (community-acquired and hospital-acquired 
pneumonia)
Nutritional deficiencies 
      Calcium 
iron 
Vitamin B12 
Magnesium
increased risk of gastric and colon cancer
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pump inhibitors. The 33 clinical studies showed significant 
heterogeneity in observed outcomes, with risk ratios for 
major adverse cardiovascular events varying from 0.64 to 
4.58  when proton pump inhibitors are used together with 
clopidogrel. The investigators stated that the result could not 
substantiate an adverse effect of proton pump inhibitor used 
on clinical outcome in patients on clopidogrel.
Because esomeprazole inhibits stomach acid   production 
and increases gastric pH, it may interfere with drugs for 
which gastric pH affects bioavailability. Digoxin absorption 
from the gastrointestinal tract is enhanced by the presence 
of gastric acid. When esomeprazole is coadministered 
with digoxin, reduced acidity may compromise digoxin 
absorption, thus decreasing its bioavailability. Therefore, 
monitoring the patient for digoxin efficacy should be con-
sidered if esomeprazole is being used concurrently with 
digoxin.52
Cost effectiveness
Although trial data have led to strong recommendations for 
the use of aspirin as a secondary prevention strategy, the data 
are less clear for the use of aspirin for primary prevention 
because the lower baseline risk of myocardial infarction 
may or may not balance out the increased risk of both 
hemorrhagic stroke and gastrointestinal bleeding. In these 
scenarios, a Framingham risk score is usually calculated to 
determine the 10-year risk of coronary heart disease and that 
risk is weighed against patients’ predisposing risk factors 
for developing an aspirin related bleeding event. In either 
scenario, adherence to daily aspirin therapy is imperative to 
ensure the cardiovascular benefits are realized. Studies have 
shown that as many as 30% of patients are not fully adherent 
to aspirin therapy with aspirin related dyspepsia being cited 
one of the main reasons for discontinuing therapy.16,17 From 
the patients’ perspective, daily aspirin therapy may be 
associated with a decrease in their quality of life and the daily 
dyspepsia symptoms may overshadow the more remote, but 
acute risks of a myocardial infarction. If this perception leads 
to discontinuation of therapy, with or without the providers’ 
knowledge, it poses an increased risk of mortality.15
Several cost-utility and cost-effectiveness studies have 
been conducted to determine if dual preventative therapy with 
aspirin and a proton pump inhibitor results in increased patient 
adherence and satisfaction, increased quality-adjusted life 
years and if the therapy is cost-effective when compared to no 
therapy or aspirin alone.53–55 A cost-utility analysis examined 
the use of aspirin with and without the addition of a proton 
pump inhibitor for primary cardiovascular disease prevention 
in men with a range of different coronary heart disease and 
gastrointestinal bleeding risks.54 Based on their model, they 
found that men taking aspirin in addition to a   proton pump 
inhibitor gained more quality-adjusted-life-years (18.67 ver-
sus 18.68), but also incurred higher costs (US $21,037 versus 
US $17,571) over their remaining lifetime. The incremental 
cost per quality-adjusted-life-years of US $447,077 suggested 
that for a 45-year old man with a 10-year, 10% CHD risk and 
average bleeding risk (defined as a risk of gastrointestinal 
bleeding mortality of 1 in 1000 patients), the addition of a 
proton pump inhibitor was not cost-effective. These results 
remained consistent across all CHD risk levels and for men 55 
and 65 years old. The authors also tested their results against 
varied baseline bleeding risks. When the baseline bleeding 
risk increased to 4 in 1000 patients, the incremental cost per 
quality-adjusted lifeyear was less than US $50,000 annually 
and became cost-effective when the risk was increased to 7 in 
1000 patients. For men greater than 55 years old, the incremen-
tal cost per quality-adjusted-life-years for prophylactic treat-
ment with a proton pump inhibitor was less than US $50,000 
annually when the bleeding risk was increased to 2 or 3 per 
1000 patients. Overall, the investigators found that adding a 
generic proton pump inhibitor for all men is not cost effective 
due to the relatively small risk of gastrointestinal bleeding. 
For men with an increased risk of bleeding, the addition of a 
proton pump inhibitor may be cost effective.
Two cost-effectiveness studies were conducted by 
Saini et al. The first study evaluated the benefit of proton pump 
inhibitors on reduction in upper gastrointestinal   bleeding risk 
for patients taking low dose aspirin for   secondary prevention.54 
They assumed an annual cost of a generic proton pump inhibi-
tor therapy to be US $250,   average age was 65 years old, and 
average bleeding risk to be 2.5 in 1000 patients. Results from 
their base case analysis showed that coadministration of a 
proton pump inhibitor is   cost-effective; however, it was not 
cost-effective in younger patients. The second study modified 
their previous model to take into account aspirin discontinua-
tion due to dyspepsia and the effect on cardiovascular events.55 
The base-case in this study assumed a patient aged 50-years 
old, taking low dose aspirin for secondary prevention with 
no risk factors for upper gastrointestinal bleeding (5 in 1000 
patients at age 65), assuming the annual cost of generic pro-
ton pump inhibitor therapy to be US $144. They estimated 
the absolute increase in adherence to aspirin therapy when 
coadministered with a proton pump inhibitor to be 2.5% when 
using published data that 20% of patients will discontinue 
aspirin therapy at 1-year and 25%–40% will discontinue by 
5 years. Compared to aspirin alone, the addition of a proton 
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pump inhibitor led to fewer upper gastrointestinal bleeding 
events, increased aspirin adherence and fewer recurrent MIs 
resulting in 38 additional days of life per patient. Much of 
this benefit was due to a reduction in cardiovascular mortality. 
The incremental cost-effectiveness ratio was US $19,000 per 
life-year saved.
Discussion and conclusion
Clinical studies have demonstrated that the addition of 
esomeprazole to low dose aspirin therapy in patients at high 
risk of developing gastric ulcers for the prevention of car-
diovascular disease, significantly reduced their risk of ulcer 
development. There are no clinical studies performed to-date 
to evaluate whether the addition of esomeprazole to low dose 
aspirin has the same efficacy in primary or secondary pre-
vention of cardiovascular events compared to aspirin alone. 
However, pharmacokinetic and pharmacodynamic studies 
suggested that with the addition of esomeprazole, there are no 
alterations in the pharmacokinetic parameters and antiplatelet 
effects of aspirin. All of these studies evaluated patients for 
a short duration. It is therefore difficult to make a definitive 
determination on the long-term clinical efficacy, safety, and 
tolerability of combination low dose aspirin and esomepra-
zole use in patients with cardiovascular disease.
For patients who require low dose aspirin therapy for 
either primary or secondary prevention of cardiovascular 
events (Table 2), it is clear that adherence to daily aspirin 
therapy is required for the mortality benefit seen in trials 
and that nonadherence is often due to gastrointestinal side 
effects (which may or may not include the development of 
peptic ulcers). Therefore, based on current data, for those 
patients who are at a high risk of developing a gastrointes-
tinal ulcer (Table 3), the benefit of adding esomeprazole to 
prevent low dose aspirin discontinuation likely outweighs 
Table 2 Summary of recommendations on aspirin use for the prevention of cardiovascular events10,11,56
Population Recommendation Level of evidence
US preventative services task force
Men 45–79 years old Encourage use of ASA* (75 mg/day) when potential  
benefit of a reduction in MI outweighs the potential  
harm of an increase in Gi hemorrhage
A
Women 55–79 years old Encourage use of ASA* (75 mg/day) when potential benefit  
of a reduction in ischemic strokes outweighs the  
potential harm of an increase in Gi hemorrhage
A
Men and Women . 80 years old Insufficient evidence to assess the balance of benefit  
and harm for CV disease prevention
i
Women , 55 years old and Do not encourage the use of ASA* for CV disease prevention D
Men , 45 years old
AHA/ACCF scientific statement 2010: primary prevention ACCF/AHA
Adults with DM and a 10-year CVD  
risk . 10% who are not at increased  
risk for bleeding
Consider low dose ASA* therapy (75 to 162 mg/day) B
Adults with DM and a 10-year CVD risk , 5% Not recommended C
Adults with DM and a 10-year CVD  
risk of 5%–10%
Consider using low dose ASA* (75 to 162 mg/day)  
until further research is available
C
ADA 2011 guidelines ADA
High CVD risk: 10-year risk . 10%  
Type 1 and 2 DM
Consider ASA* therapy at 75 to 162 mg/day C
Low CVD risk 10-year risk , 5% Risk of bleed outweighs benefit; not recommended C
Moderate CVD risk 10-year risk 5%–10% Clinical judgment of risk versus benefit required E
Secondary prevention: all patients with  
DM and history of CVD
Use ASA* 75–162 mg/day A
Documented ASA* allergy in patients with  
DM and h/o CVD
Use clopidogrel 75 mg/day B
Patients with DM and ACS Combination therapy with ASA* (75–162 mg/day) and 
clopidogrel 75 mg/day) up to one year
B
Notes: ASA* is contraindicated in patients ,21 years old due to the risk of Reye’s syndrome. A: benefit is substantial; B: benefit is moderate; C: benefit is small; D: Harm 
outweighs benefit; I: Insufficient evidence. ACCF/AHA - A: data from many large, randomized controlled trials; B: data from fewer, smaller randomized controlled trials, 
non-randomized studies or observational registries; C: expert consensus. ADA – A: clear evidence randomized controlled trial or meta-analysis; B: supportive evidence from 
cohort studies; C: supportive evidence from poorly controlled or uncontrolled studies; E: expert consensus.
Abbreviations: ACCF, American College of Cardiology Fellows; ACS, acute coronary syndrome; ADA, American Diabetes Association; AHA, American Heart Association; 
ASA, aspirin; CVD, cardiovascular disease; DM, diabetes mellitus; Gi, gastrointestinal; h/o, history of; Mi, myocardial infarction.
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the risks of longer term proton pump inhibitor use. In these 
high-risk patients, the extra cost to both the patient and 
the healthcare system may be justified by the reduction in 
associated cardiovascular mortality and the combination can 
be recommended. The addition of esomeprazole to a low 
dose aspirin   regimen may be a more appropriate choice 
than the fixed dose combination capsule as it allows each 
individual medication dose to be titrated easily. In addition, 
giving the two agents separately may be more economical 
from a patient cost   perspective since both medications cur-
rently have generic alternatives. Fixed dose combination 
therapy has the   potential to further improve medication 
regimen adherence, but this has not been formally evalu-
ated to determine if the benefit from improved adherence 
outweighs the potential increased cost of the fixed combina-
tion therapy and will have to be determined by individual 
patient   preference. On the other hand, for those patients at 
lower risk of developing a   gastrointestinal ulcer, both the 
additional risk and cost make the inclusion of a proton pump 
inhibitor unwarranted.
In addition, the USPSTF recommendation statement 
provided 10-year CHD risk levels where the number of 
cardiovascular disease events prevented is balanced by the 
number of serious bleeding events.10 They recommend that 
this is the point where shared decision making between the 
provider and patient is necessary. For these patients who 
would likely benefit from long term low dose aspirin therapy, 
the addition of a proton pump inhibitor may abrogate the 
increased bleeding risk. Similarly, patients who have one or 
more risk factors for gastrointestinal bleeding, but who have 
a high 10-year risk of CHD or strong family history of CHD, 
may also benefit from the addition of a proton pump inhibitor 
rather than switching to either an alternative regimen such as 
clopidogrel or forgoing the benefit of primary prevention with 
antiplatelet therapy.
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